Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
Competitive Advantages in Efficacy Will Drive Prescription Rates, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, following its approval in early 2009, Centocor/Janssen-Cilag's ustekinumab will become the clinical gold standard for psoriasis by 2011. Ustekinumab will achieve gold standard status because of its competitive advantages in long-term efficacy over Centocor/Schering- Plough/Mitsubishi Tanabe's Remicade and due to its superior effect on plaque clearance when compared to Amgen/Wyeth/Takeda's Enbrel.
According to the new report entitled Psoriasis: Ustekinumab to Emerge as New Clinical Gold Standard by 2011, ustekinumab has competitive advantages in efficacy, the area of the highest importance to surveyed physicians, and a superior safety and delivery profile when compared to Remicade. Surveyed dermatologists report that a drug's effect on plaque clearance is the attribute that most influences their prescribing decisions in psoriasis and clinical data shows that ustekinumab has advantages over sales-leading Enbrel on this attribute.
"Clinical data and thought leader opinion indicate that ustekinumab and Abbott/Eisai's Humira outperform Enbrel on efficacy and delivery measures," said Irene Koulinska, analyst at Decision Resources. "But the major improvement in efficacy offered by ustekinumab will earn it future gold-standard status."
About the Report
Psoriasis: Ustekinumab to Emerge as New Clinical Gold Standard by 2011 is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
[MEDX royalty supposed to be somewhere in the 3-5 % interval] |
